Companion Diagnostics Market Size, Share & Forecast 2035

What is the Companion Diagnostics Market?

Companion diagnostics are medical tests used to determine whether a patient will respond effectively to a specific drug or targeted therapy. These diagnostic tools identify biomarkers such as genetic mutations, protein expression, or molecular signatures that influence treatment outcomes.

The Companion Diagnostics Market represents a specialized segment within the molecular diagnostics and precision medicine industry. These tests are developed alongside pharmaceutical therapies to help physicians select the most effective treatment for individual patients.

Companion diagnostics play a critical role in personalized healthcare, particularly in oncology where treatment success often depends on identifying specific genetic mutations. Regulatory authorities such as the U.S. FDA increasingly require companion diagnostics for certain targeted therapies to ensure treatment safety and effectiveness.

As healthcare systems move toward data-driven and patient-centric medicine, companion diagnostics are becoming essential tools for optimizing therapeutic outcomes and reducing ineffective treatments.

Companion Diagnostics Market Size, Share & Trends Analysis (2025–2035)

Quick Market Snapshot

Companion Diagnostics Market Size and Growth Forecast

The global Companion Diagnostics Market was valued at USD 7.91 billion in 2025 and is projected to reach USD 25.69 billion by 2035, expanding at a compound annual growth rate (CAGR) of 12.5% between 2026 and 2035.

This strong market growth is supported by increasing adoption of precision medicine, biomarker discovery, and targeted drug therapies.

Key Growth Trends

• Rapid expansion of precision oncology therapies

• Increasing use of next-generation sequencing (NGS)

• Growing collaboration between pharmaceutical and diagnostic companies

• Rising adoption of biomarker-based treatment selection

Pharmaceutical companies increasingly develop co-approved diagnostic tests alongside targeted drugs, creating strong demand for companion diagnostics worldwide.

Key Drivers of the Companion Diagnostics Market

Rising Global Cancer Prevalence

Cancer remains one of the leading causes of death worldwide. Targeted therapies require companion diagnostics to identify eligible patients based on specific biomarkers.

These diagnostic tests help:

• Identify suitable patients for targeted drugs

• Improve treatment success rates

• Reduce unnecessary treatment costs

As oncology drug pipelines expand, demand for biomarker testing and companion diagnostics continues to grow.

Expansion of Precision Medicine

Precision medicine focuses on tailoring healthcare decisions based on genetics, lifestyle, and disease characteristics.

Companion diagnostics enable physicians to:

• Match therapies with patient biomarkers

• Predict drug response

• Avoid ineffective treatments

Government initiatives such as the Precision Medicine Initiative have accelerated research in this area.

Advancements in Molecular Diagnostic Technologies

Technological innovations have significantly improved the accuracy and speed of diagnostic testing.

Major advancements include:

• Next-generation sequencing

• digital PCR technologies

• biomarker discovery platforms

• AI-driven genomic analysis

These innovations allow healthcare providers to identify multiple genetic mutations simultaneously, supporting personalized treatment planning.

Strategic Partnerships Between Pharma and Diagnostics Companies

Pharmaceutical companies increasingly collaborate with diagnostic developers to create co-approved companion diagnostics.

These collaborations accelerate:

• clinical trial biomarker testing

• drug approval processes

• commercialization of targeted therapies

Such partnerships are expected to significantly expand the companion diagnostics market over the next decade.

Companion Diagnostics Market Segmentation by Offering

The market can be segmented based on products and services.

Products Segment

Products represent the largest market share because they include the essential diagnostic tools used in biomarker testing.

Key product categories include:

• diagnostic assay kits

• reagents

• genomic testing platforms

• molecular diagnostic instruments

Services Segment

Services include laboratory testing and research services provided by reference laboratories and contract research organizations.

The services segment is growing due to increasing demand for specialized molecular testing capabilities.

Technologies Used in Companion Diagnostics

Several advanced technologies are widely used in companion diagnostic testing.

Polymerase Chain Reaction (PCR)

PCR technology enables rapid detection of specific genetic mutations associated with targeted therapies.

Immunohistochemistry (IHC)

IHC detects protein expression in tissue samples, helping physicians determine tumor characteristics and treatment options.

In Situ Hybridization (ISH)

ISH is used to detect DNA or RNA sequences within tissue samples, making it valuable for identifying gene amplifications in cancer diagnostics.

Next-Generation Sequencing (NGS)

NGS is one of the most advanced diagnostic technologies, enabling simultaneous analysis of multiple genes and mutations.

NGS supports:

• comprehensive genomic profiling

• personalized treatment planning

• biomarker discovery

Disease Areas Driving Demand for Companion Diagnostics

Companion diagnostics are used across several disease areas.

Oncology

Oncology accounts for the largest share of the companion diagnostics market due to the widespread use of targeted therapies.

Examples include testing for:

• HER2 mutations

• EGFR mutations

• ALK rearrangements

Major End Users in the Companion Diagnostics Market

The market serves several healthcare stakeholders.

Pharmaceutical and Biopharmaceutical Companies

Drug developers rely on companion diagnostics during clinical trials and drug commercialization.

Reference Laboratories

Reference labs provide high-volume diagnostic testing services using advanced molecular technologies.

Contract Research Organizations (CROs)

CROs support pharmaceutical companies by performing biomarker testing during clinical trials.

Other end users include:

• hospitals

• diagnostic laboratories

• academic research institutions

Regional Analysis of the Companion Diagnostics Market

North America

North America holds the largest market share due to:

• advanced healthcare infrastructure

• strong pharmaceutical R&D

• early adoption of precision medicine

Europe

Europe represents a significant market driven by investment in molecular diagnostics and supportive regulatory frameworks.

Asia Pacific

Asia Pacific is expected to be the fastest-growing region, supported by:

• rising healthcare expenditure

• increasing cancer prevalence

• expanding diagnostic infrastructure

Latin America and Middle East & Africa

These regions are emerging markets where improving healthcare access and growing awareness of personalized medicine are expected to drive demand.

Key Companies in the Companion Diagnostics Market

Major companies operating in the global market include:

• Abbott

• F. Hoffmann-La Roche Ltd.

• Agilent Technologies

• Illumina Inc.

• Guardant Health

• Thermo Fisher Scientific

• bioMérieux

• QIAGEN

• Myriad Genetics

These companies focus on:

• biomarker discovery

• molecular diagnostics innovation

• strategic collaborations with pharmaceutical firms

Continuous product innovation and regulatory approvals are expected to intensify competition within the industry.

Key Takeaways

• Companion diagnostics enable personalized treatment decisions

• The market is projected to reach USD 25.69 billion by 2035

• Oncology remains the largest application segment

• Next-generation sequencing is the fastest-growing technology

• Asia Pacific is expected to be the fastest-growing regional market

FAQs

What are companion diagnostics?

Companion diagnostics are laboratory tests that identify biomarkers to determine whether a patient will respond to a specific drug or therapy.

Why are companion diagnostics important?

They enable personalized treatment by helping physicians select therapies that are most likely to be effective for individual patients.

Which technology is most advanced in companion diagnostics?

Next-generation sequencing (NGS) is considered the most advanced technology because it allows comprehensive genomic analysis.

Which region dominates the market?

North America currently dominates the global companion diagnostics market due to strong research infrastructure and high adoption of precision medicine.

What is the future outlook for the companion diagnostics market?

The market is expected to grow significantly, reaching USD 25.69 billion by 2035, driven by biomarker research, targeted therapies, and genomic technologies.

About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analysis provides the essential framework for organizations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organization remains agile, proactive, and poised for success in today’s competitive market.

Don’t miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organization’s future success by acquiring one of our Expert Market Research reports today.

Media Contact

Company Name: Claight Corporation

Contact Person: Deepanshu Choudhary, Business Consultant

email: sales@expertmarketresearch.com

Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790

Address: 30 North Gould Street, Sheridan, WY 82801, USA

website: www.expertmarketresearch.com

Author name- Deepanshu Choudhary